NF2 and schwannomatosis: First identified in patients with NF2-related schwannomatosis in the early 1990s, many studies have since sought out the pathways altered by loss of the NF2 gene product Merlin and have demonstrated its role in a number of known oncogenic pathways in vitro, including Ras/Raf/MEK/ERK11, mTORC1/212, Rac/p21-PAK/c-Jun Kinase13, PI3K/AKT14, and Wnt/β-catenin15.